HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...

In an exclusive interview with Business Today, D. Sridhar Babu, Minister for Information Technology, Industries and Commerce, ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Eli Lilly (LLY) stock in focus as its diabetes drug Mounjaro causes heart benefits suceeding in a late-stage trial versus its ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after ...

BENGALURU (IANS) – US firms are increasingly choosing India for their office spaces, with Bengaluru, Hyderabad, and Delhi-NCR being the top preferred cities.